Revenue, 2024 (US$M)
$0.0
Forecast, 2030 (US$M)
$0.0
CAGR, 2025 - 2030
-100%
Report Coverage
Mexico

Mexico women’s health market highlights

  • The Mexico women’s health market generated a revenue of USD 514.5 million in 2023 and is expected to reach USD 863.6 million by 2030.
  • The Mexico market is expected to grow at a CAGR of 7.7% from 2024 to 2030.
  • In terms of segment, contraceptives was the largest revenue generating application in 2023.
  • Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.


Women’s health market data book summary

Market revenue in 2023USD 514.5 million
Market revenue in 2030USD 863.6 million
Growth rate7.7% (CAGR from 2023 to 2030)
Largest segmentContraceptives
Fastest growing segmentEndometriosis & Uterine Fibroids
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationHormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS)
Key market players worldwideAbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring


Other key industry trends

  • In terms of revenue, Mexico accounted for 1.2% of the global women’s health market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Latin America, Brazil women’s health market is projected to lead the regional market in terms of revenue in 2030.
  • Mexico is the fastest growing regional market in Latin America and is projected to reach USD 863.6 million by 2030.

Contraceptives was the largest segment with a revenue share of 42.93% in 2024. Horizon Databook has segmented the Mexico women's health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.


Mexico’s pharmaceutical industry is the second-largest pharmaceutical industry in Latin America. Its growth is primarily due to the local presence of key market players, an increasing number of startups, and rising investments.

For instance, in October 2023, Merck KGaA launched a comprehensive Fertility Benefit program that will offer financial support to its employees and partners for fertility treatments in eight major markets: the UK, Germany, China, India, Mexico, Brazil, Switzerland, and Taiwan.

Women are at a higher risk of reproductive complications in this country. Government initiatives pertaining to reforming women’s health are expected to raise awareness and educate women regarding female reproductive health.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Women's Health Market Scope

Women's health market segmentation & scope
Application
Hormonal Infertility
Contraceptives
Postmenopausal Osteoporosis
Endometriosis & Uterine Fibroids
Menopause
Polycystic Ovary Syndrome (PCOS)
Drug Class
Hormonal Therapies
Bone Health Agents
Fertility Agents
GnRH Modulators
Pain and Symptom Management
Metabolic Agents
Others
Age
50 years and above
Postmenopausal Osteoporosis
Endometriosis & Uterine Fibroids
Menopause
Others
Others

Women's Health Market Companies

Name Profile # Employees HQ Website

Mexico women's health market

Mexico Women's Health Market Outlook Share, 2024 & 2030 (US$M)

Mexico women's health market

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more